"Oncoinvent Announces Dosing of First Patient with Radspherin® in Phase 1 Clinical Trial

Press Release 02.2020: Radiopharmaceutical company starts first-in-human trial in colorectal patients suffering from peritoneal carcinomatosis

Oncoinvent AS, a clinical stage radiopharmaceutical company developing novel radioisotope-based therapies to provide new therapeutic options for cancer patients, today announced that the first patient has been dosed in the phase 1, first-in-human clinical trial of it’s lead candidate compound Radspherin®."

Da er vi i gang!